Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Dopamine D1 receptor – NMDA receptor GluN1 subunit protein-protein interface is a specialized molecular complex formed by the direct physical coupling of the G protein-coupled Dopamine D1 receptor (D1R) and the ionotropic NMDA receptor subunit 1 (GluN1). This interaction occurs via the carboxyl-terminal tails of both receptors and plays a critical role in modulating glutamatergic neurotransmission and synaptic plasticity in the central nervous system, particularly within the striatum and hippocampus (Lee et al., 2002, Cell). By forming this complex, D1R activation can either enhance or inhibit NMDA receptor-mediated currents, thereby regulating neuronal excitability and long-term potentiation (LTP). Dysregulation of the D1R-GluN1 interface is strongly linked to the pathophysiology of schizophrenia, where it contributes to NMDA receptor hypofunction, and to Parkinson's disease, where it may influence the development of L-DOPA-induced dyskinesia (Pei et al., 2004, Journal of Neuroscience). Therapeutic targeting of this interface using interference peptides, such as Tat-D1-t2, offers a precise method to decouple these signaling pathways without the broad side effects of global receptor agonists or antagonists (Nai et al., 2010, Molecular Brain). This target is of significant interest for developing treatments that restore cognitive function and motor control by fine-tuning the crosstalk between dopaminergic and glutamatergic systems.
Modulation of NMDA receptor-mediated signaling through the physical disruption or stabilization of the direct interaction between the C-terminal tails of the Dopamine D1 receptor and the GluN1 subunit (Lee et al., 2002, Cell).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopamine D1 receptor – NMDA receptor GluN1 subunit protein-protein interface (D1R-GluN1 PPI) (D1R-GluN1 PPI).